The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b/2, open-label study of selective Axl, Mer and CSF1R inhibitor adrixetinib (Q702) in combination with intravenous pembrolizumab in patients with selected advanced solid tumors: Results of a phase 1 study (QRNT-008).
 
Hong Jae Chon
Consulting or Advisory Role - Aptamer Sciences Inc; AstraZeneca; Bayer; BeiGene; BMS; Eisai; MSD; Ono Pharmaceutical; Roche; Sanofi; SERVIER
Speakers' Bureau - AstraZeneca; Bayer; BMS; Dong-A ST; Eisai; Roche; Sanofi; SERVIER
Research Funding - BeiGene (Inst); Boryung (Inst); Dong-A ST (Inst); Hanmi (Inst); inno-n (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Medivir (Inst)
 
Seung Kim
No Relationships to Disclose
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Daiichi Sankyo; Eisai; indivumed; LG Chem; MSD Oncology; Ono Pharmaceutical; Toray Industries
Speakers' Bureau - Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; BMS/Ono; Daiichi Sankyo/UCB Japan; Eisai; MSD Oncology
Research Funding - Amgen (Inst); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daichii Sankyo; Eisai; Indivumed; Lilly; MSD Oncology; Roche/Genentech; Sillajen; Zymeworks
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Anthony El-Khoueiry
Honoraria - Agenus; AstraZeneca/MedImmune; Bristol-Myers Squibb; EISAI; Elevar Therapeutics; Exelixis; Merck; Qurient; Roche/Genentech; Senti Biosciences; SERVIER; TERUMO
Consulting or Advisory Role - Agenus; AstraZeneca/MedImmune; Bristol-Myers Squibb; Eisai; Elevar Therapeutics; Exelixis; Genentech; Merck; Qurient; Roche; Senti Biosciences; SERVIER; TERUMO
Research Funding - Astex Pharmaceuticals; AstraZeneca; Auransa; Fulgent Genetics
Travel, Accommodations, Expenses - Affimed Therapeutics
 
Do-Youn Oh
Consulting or Advisory Role - Abbvie; Alligtor Bioscience AB; Arcus Biosciences; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Eutilex; Genentech/Roche; Halozyme; Hana Pharm; Idience; IQVIA; J-Pharma; LG Chem; Merck Serono; Mirati Therapeutics; Moderna Therapeutics; MSD Oncology; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Jaspreet Grewal
Honoraria - Bristol-Myers Squibb/Roche; Curio Science
Consulting or Advisory Role - Castle Biosciences
Speakers' Bureau - Bristol-Myers Squibb/Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Roche; Castle Biosciences
 
Jeongjun Kim
Employment - Qurient
Stock and Other Ownership Interests - Qurient
 
Hyunji (Karen) Ahn
Employment - Qurient
Stock and Other Ownership Interests - Qurient
 
Seung-Hee Ryu
Employment - Qurient
 
Jinho Choi
Employment - Qurient
 
Kiyean Nam
Employment - Qurient
Leadership - Qurient
Stock and Other Ownership Interests - Qurient
Patents, Royalties, Other Intellectual Property - Being listed as an author of multiple patents published by employer company Qurient